{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05182073",
            "orgStudyIdInfo": {
                "id": "FT576-101"
            },
            "organization": {
                "fullName": "Fate Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "FT576 in Subjects With Multiple Myeloma",
            "officialTitle": "A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "in-subjects-with-multiple-myeloma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2040-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-15",
            "studyFirstSubmitQcDate": "2022-01-05",
            "studyFirstPostDateStruct": {
                "date": "2022-01-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Fate Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma",
                "Myeloma"
            ],
            "keywords": [
                "Multiple Myeloma",
                "daratumumab",
                "CAR NK cell",
                "cellular therapy",
                "relapsed/refractory multiple myeloma",
                "allogeneic natural killer cells",
                "anti-CD38 monoclonal antibody",
                "chimeric antigen receptor (CAR)",
                "BCMA",
                "anti-B-cell maturation antigen (BCMA)",
                "natural killer (NK) cell"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 168,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Regimen A",
                    "type": "EXPERIMENTAL",
                    "description": "FT576 single dose monotherapy in subjects with r/r MM",
                    "interventionNames": [
                        "Drug: FT576 (Allogenic CAR NK cells with BCMA expression)",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Bendamustine"
                    ]
                },
                {
                    "label": "Regimen A1",
                    "type": "EXPERIMENTAL",
                    "description": "FT576 multiple dose monotherapy in subjects with r/r MM",
                    "interventionNames": [
                        "Drug: FT576 (Allogenic CAR NK cells with BCMA expression)",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Bendamustine"
                    ]
                },
                {
                    "label": "Regimen B",
                    "type": "EXPERIMENTAL",
                    "description": "FT576 single dose in combination with daratumumab in subjects with r/r MM",
                    "interventionNames": [
                        "Drug: FT576 (Allogenic CAR NK cells with BCMA expression)",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Daratumumab",
                        "Drug: Bendamustine"
                    ]
                },
                {
                    "label": "Regimen B1",
                    "type": "EXPERIMENTAL",
                    "description": "FT576 multiple dose in combination with daratumumab in subjects with r/r MM",
                    "interventionNames": [
                        "Drug: FT576 (Allogenic CAR NK cells with BCMA expression)",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Daratumumab",
                        "Drug: Bendamustine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FT576 (Allogenic CAR NK cells with BCMA expression)",
                    "description": "Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).",
                    "armGroupLabels": [
                        "Regimen A",
                        "Regimen A1",
                        "Regimen B",
                        "Regimen B1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Conditioning Agent",
                    "armGroupLabels": [
                        "Regimen A",
                        "Regimen A1",
                        "Regimen B",
                        "Regimen B1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Conditioning Agent",
                    "armGroupLabels": [
                        "Regimen A",
                        "Regimen A1",
                        "Regimen B",
                        "Regimen B1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Daratumumab",
                    "description": "Anti-CD38 Monoclonal Antibody",
                    "armGroupLabels": [
                        "Regimen B",
                        "Regimen B1"
                    ],
                    "otherNames": [
                        "Darzalex",
                        "Darzalex Faspro"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bendamustine",
                    "description": "Conditioning Agent",
                    "armGroupLabels": [
                        "Regimen A",
                        "Regimen A1",
                        "Regimen B",
                        "Regimen B1"
                    ],
                    "otherNames": [
                        "Bendeka",
                        "Treanda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD",
                    "timeFrame": "Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1"
                },
                {
                    "measure": "Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts",
                    "timeFrame": "From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)"
                },
                {
                    "measure": "Incidence, nature, and severity of adverse events",
                    "timeFrame": "Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "Proportion of subjects with a best overall response of sCR, CR, VGPR, or PR, as determined by the investigator according to standard IMWG response criteria",
                    "timeFrame": "From baseline tumor assessment up to approximately 2 years after last dose of FT576"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "Duration from the first occurrence of a documented objective response until the time of disease progression or relapse, or death due to progressive disease, as determined by the investigator according to standard IMWG response criteria",
                    "timeFrame": "Up to 15 years"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Time from first dose of study treatment to disease progression or relapse, or to the day of death from any cause, as determined by the investigator according to standard IMWG response criteria",
                    "timeFrame": "Up to 15 years"
                },
                {
                    "measure": "Relapse-free survival (RFS) from complete response (CR)",
                    "description": "Duration from the start of sCR or CR until the time of relapse from sCR or CR, as determined by the investigator according to standard IMWG response criteria",
                    "timeFrame": "Up to 15 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Time from first dose of study treatment to death from any cause",
                    "timeFrame": "Up to 15 years"
                },
                {
                    "measure": "Pharmacokinetics (PK) of FT576",
                    "description": "Concentration of FT576 in peripheral blood following FT576 administration",
                    "timeFrame": "From Baseline to PTFU visit of last cycle on the study treatment (End of cycle is Day 29 from Day 1 FT576 infusion of this cycle)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "* Abbreviated inclusion criteria:\n\nDiagnosis of r/r MM with measurable disease by at least one of the following:\n\n* Serum M-protein \u22651.0 g/dL\n* Urine M-protein \u2265200 mg/24 hours\n* Involved serum free light chain level \u226510 mg/dL, with an abnormal kappa-lambda ratio if the serum M-protein \\<1.0 g/dL and/or urine M-protein \\<200 mg/24 hours\n* Regimens A and A1: MM relapsed or progressed after \u22653 prior approved therapies, including an IMiD, proteosome inhibitor, and anti-CD38 mAb\n* Regimens B and B1: MM relapsed or progressed after \u22652 prior approved therapies, including an IMiD and proteosome inhibitor\n\nNote: for all Regimens, prior BCMA CAR T-cell therapy and BCMA-targeted therapy (e.g., bi-specific engagers or antibody-drug conjugates) is allowed\n\n\\* Abbreviated exclusion criteria:\n\nEastern Cooperative Oncology Group Performance Status (ECOG PS) \u22652\n\nEvidence of insufficient hematologic function:\n\n* ANC \\<1000/\u00b5L without growth factor support \u22647 days prior to measurement\n* Platelet count \\<75,000/\u00b5L without platelet transfusion \u226472 hours prior to measurement\n\nEvidence of insufficient organ function\n\n* CrCL \\<50 ml/min by Cockcroft-Gault or other institutional method\n* T bilirubin \\>1.5x ULN, except for Gilbert's syndrome\n* AST \\>3x ULN or ALT \\>3x ULN, unless directly due to underlying malignancy\n* O2 sat \\<92% on room air\n\nClinically significant cardiovascular disease:\n\n* Myocardial infarction within 6 months of first treatment\n* Unstable angina or CHF of NYHA Grade 2 or higher\n* Cardiac EF \\<40%\n\nSubjects with active central nervous system (CNS) , including leptomeningeal disease. Subjects with prior CNS involvement may be enrolled into the study if effective treatment of their CNS disease was completed at least 3 months prior to Day 1 with no evidence of disease clinically and at least stable findings on relevant CNS imaging.\n\nNon-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment\n\nCurrently receiving or likely to require immunosuppressive therapy (e.g., prednisone \\>5 mg daily) for any reason during the treatment period, with the exception of corticosteroids.\n\nClinically significant infections, including:\n\n* HIV positive by serology\n* HBV positive by serology or PCR\n* HCV positive by serology or PCR\n\nLive vaccine \\<6 weeks prior to start of conditioning\n\nReceipt of an allograft organ transplant\n\nOngoing requirement for systemic graft -versus-host disease therapy\n\nPlasma cell leukemia defined as a plasma cell count \\>2000/mm\\^3\n\nPrior malignancy (other than current indication including any antecedent hematologic disorder) within the 2 years prior to enrollment except for the following: basal or squamous cell carcinomas of the skin, carcinoma in situ of the cervix or breast treated with curative intent, or localized prostate cancer treated with curative intent, or malignancy that, in the opinion of the investigator and Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years.\n\nWashout periods from prior therapies:\n\n* For all subjects (Regimens A, A1, B and B1), receipt of the following: Chemotherapy, or radiation therapy, except for palliative purposes, within 14 days prior to the first dose of FT576 (Day 1) or five half-lives, whichever is shorter; Investigational therapy within 30 days prior to the first dose of FT576 study treatment or five half-lives, whichever is shorter; Biologic therapy (except for anti-CD38 mAbs in Regimen B and B1), including autologous cellular immunotherapy (e.g. CAR-T/ CAR-NK), antibody-drug conjugates or bi-specific immune-cell engaging antibody within 30 days prior to first dose of FT576 (Day 1) or half -lives whichever is shorter. prior allogenic HSCT or allogenic CAR-T/CAR-NK within 6 months of first dose of FT576 (Day1).\n* For subjects in Regimens B and B1 only, receipt of the following: Anti-CD38 therapy alone or in combination within 3 months prior to the start of daratumumab",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fate Trial Disclosure",
                    "role": "CONTACT",
                    "phone": "866-875-1800",
                    "email": "FateTrialDisclosure@fatetherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Fate Trial Disclosure",
                    "affiliation": "Fate Therapeutics, Inc",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Scri-Cbci",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Medical Oncology Hematology Consultants",
                    "status": "RECRUITING",
                    "city": "Newark",
                    "state": "Delaware",
                    "zip": "19713",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.68372,
                        "lon": -75.74966
                    }
                },
                {
                    "facility": "Indiana University",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Saint Paul",
                    "state": "Minnesota",
                    "zip": "55108",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.94441,
                        "lon": -93.09327
                    }
                },
                {
                    "facility": "Washington University",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Roswell Park",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Oncology Hematology Care, Inc",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Tennessee Oncology - Nashville",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Texas Oncology-Medical City Dallas",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Virginia Oncology Associates",
                    "status": "RECRUITING",
                    "city": "Norfolk",
                    "state": "Virginia",
                    "zip": "23502",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.84681,
                        "lon": -76.28522
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "ASH Dec 2020 Abstract",
                    "url": "https://ash.confex.com/ash/2020/webprogram/Paper142750.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069461",
                    "term": "Bendamustine Hydrochloride"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "C000556306",
                    "term": "Daratumumab"
                },
                {
                    "id": "D000000911",
                    "term": "Antibodies, Monoclonal"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M430",
                    "name": "Bendamustine Hydrochloride",
                    "asFound": "Inserted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "asFound": "Diffusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M272211",
                    "name": "Daratumumab",
                    "asFound": "Diffusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}